Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
Status:
Terminated
Trial end date:
2021-08-26
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of Xalkori (crizotinib) either with Votrient (pazopanib) or Alimta (pemetrexed)
or of the combination of 3 study drugs that can be given to patients with advanced cancer.
The safety of these drug combinations will also be studied.
Crizotinib is designed to block a protein called ALK, which is involved in cancer cell growth
and survival.
Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for
tumor growth. This may prevent or slow the growth of cancer cells.
Pemetrexed is designed to block proteins that may cause tumors to grow.
This is an investigational study. Crizotinib is FDA approved and commercially available for
the treatment of locally advanced or metastatic non-small cell lung cancer. Pazopanib is FDA
approved and commercially available for treatment of advanced renal cell carcinoma.
Pemetrexed is FDA approved and commercially available for the treatment of non-small cell
lung cancer.
The combination of crizotinib with pazopanib, crizotinib with pemetrexed, pazopanib with
pemetrexed, and giving all 3 drugs together to patients with advanced cancer is
investigational.
Up to 364 patients will take part in this study. All will be enrolled at MD Anderson.